Amphastar Pharmaceuticals AMPH CN — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's cn — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's CN — revenue?
- Amphastar Pharmaceuticals (AMPH) reported CN — revenue of $2.48M in Q1 2026.
- How has Amphastar Pharmaceuticals's CN — revenue changed year-over-year?
- Amphastar Pharmaceuticals's CN — revenue increased by 2964.2% year-over-year, from $81K to $2.48M.
- What is the long-term trend for Amphastar Pharmaceuticals's CN — revenue?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's CN — revenue has grown at a -14.7% compound annual growth rate (CAGR), from $6.02M to $3.18M.
- What does CN — revenue mean?
- This metric represents the total gross income generated from the sale of goods and services within the specified geographic or operational segment. It serves as a primary indicator of market demand and the commercial success of the company's product portfolio in this specific region. Tracking this revenue stream helps investors evaluate the segment's contribution to overall corporate growth and its ability to maintain market share.